TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22057385

Group type: EXPERIMENTAL
Intervention: Rotating platform mobile bearing TKA (Group A, n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fixed bearing TKA (Group B, n = 40)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Rotating platform mobile bearing TKA (Group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fixed bearing TKA (Group B)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 20519098

Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg/d)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Prednisolone (5 mg/d)
Number of subjects: 34
Study: 18786264

Group type: EXPERIMENTAL
Intervention: Visual impairment
Number of subjects: 14394

Group type: COMPARATOR
Intervention: Good vision (Control)
Number of subjects: 14394

Group type: EXPERIMENTAL
Intervention: Visual impairment (adjusted for a wide range of potential explanatory factors)
Number of subjects: 14394

Group type: EXPERIMENTAL
Intervention: Visual impairment (adjusted for a limited range of confounding factors)
Number of subjects: 14394
Study: 15721112

Group type: COMPARATOR
Intervention: FilterWire EX
Number of subjects: 572

Group type: COMPARATOR
Intervention: GuardWire
Number of subjects: 572
Study: 12872610

Group type: EXPERIMENTAL
Intervention: HES 200/0.5/13
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HES 70/0.5/4
Number of subjects: 20

Group type: COMPARATOR
Intervention: HES 200/0.5/13 and HES 70/0.5/4
Number of subjects: 20
Study: 10597203

Group type: EXPERIMENTAL
Intervention: Risk factor analysis by experts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimized CT staging by experienced investigators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of biological risk factor analysis and CT staging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk factor analysis and/or CT staging in non-specialized centers
Number of subjects: 0
Study: 7489937

Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg daily
Number of subjects: 2435

Group type: EXPERIMENTAL
Intervention: Aspirin 1200 mg daily
Number of subjects: 2435

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2435
Study: 1792400

Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Thiopental 5 mg/kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Etomidate 0.3 mg/kg
Number of subjects: 20
Study: 6113479

Group type: EXPERIMENTAL
Intervention: Cuff blood pressure measurements
Number of subjects: 59

Group type: COMPARATOR
Intervention: Ambulatory blood pressure monitoring
Number of subjects: 59
Study: 30883334

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Dry needling (DN)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 70
Study: 28544128

Group type: EXPERIMENTAL
Intervention: Cetuximab with radiation therapy followed by adjuvant cetuximab and irinotecan (5,940 cGy radiation, cetuximab weekly, irinotecan daily for 5 days per week for 2 weeks every 21 days for 30 weeks)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Historical controls for overall survival comparison
Number of subjects: 45
Study: 25869284

Group type: EXPERIMENTAL
Intervention: Continuous dosing of pomalidomide/dexamethasone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent dosing of pomalidomide/dexamethasone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pomalidomide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both dosing regimens (continuous and intermittent)
Number of subjects: 0
Study: 23677919

Group type: EXPERIMENTAL
Intervention: Raltegravir intensification
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (same regimen)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Delayed-intensification arm (after 24 weeks of control)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Both arms (Raltegravir and Control)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Increases in CD4 T cell counts
Number of subjects: 44
Study: 22773702

Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 20025778

Group type: EXPERIMENTAL
Intervention: Oxytocin (intranasal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17488782

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 microg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 microg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Slow-release oral misoprostol (800 microg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional misoprostol (vaginal or sublingual)
Number of subjects: 33
Study: 15130977

Group type: EXPERIMENTAL
Intervention: Training care givers in basic nursing and facilitation of personal care techniques
Number of subjects: 300
Study: 11239194

Group type: EXPERIMENTAL
Intervention: Contralateral carotid endarterectomy (CEA)
Number of subjects: 19
Study: 9549794

Group type: COMPARATOR
Intervention: Functional restoration program (Project A)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Functional restoration program (Project B)
Number of subjects: 238
Study: 7944416

Group type: EXPERIMENTAL
Intervention: OK-432 administered preoperatively via hepatic artery
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no treatment with OK-432)
Number of subjects: 10
Study: 3284269

Group type: EXPERIMENTAL
Intervention: 1 mg/kg thiopentone
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 2.5 mg/kg thiopentone
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 33
Study: 2177499

Group type: EXPERIMENTAL
Intervention: Low-dose doxycycline capsules (administered daily for 2 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo capsules (administered daily for 2 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose doxycycline capsules (in vitro exposure)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose doxycycline capsules (in additional subjects)
Number of subjects: 0
Study: 9583

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 0
Study: 31471729

Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM) intervention
Number of subjects: 1379

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1379
Study: 27711048

Group type: EXPERIMENTAL
Intervention: RG7713 (20 mg intravenous dose)
Number of subjects: 19
Study: 25198284

Group type: EXPERIMENTAL
Intervention: UC plus standard prize CM (average expected prize earnings about $300)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: UC plus high magnitude prize CM (average expected prize earnings about $900)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: UC plus voucher CM (expected maximum of about $900 in vouchers)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: All CM conditions
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: CM conditions
Number of subjects: 240
Study: 23274594

Group type: EXPERIMENTAL
Intervention: Hypohydrated hot (HYH)
Number of subjects: 12

Group type: COMPARATOR
Intervention: All conditions
Number of subjects: 12
Study: 21029512

Group type: EXPERIMENTAL
Intervention: Pramipexole (n=7)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (n=8)
Number of subjects: 15
Study: 19841457

Group type: EXPERIMENTAL
Intervention: Lower tidal volume (Vt) ventilation
Number of subjects: 3596

Group type: COMPARATOR
Intervention: Higher PEEP
Number of subjects: 3596
Study: 16797484

Group type: EXPERIMENTAL
Intervention: Metacognitive style of rumination
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Acceptance
Number of subjects: 80

Group type: COMPARATOR
Intervention: No training control
Number of subjects: 80
Study: 15539964

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: ER niacin 2 g monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg plus ER niacin 2 g
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg plus ER niacin 0.5-2 g
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosuvastatin monotherapy
Number of subjects: 0
Study: 11686658

Group type: EXPERIMENTAL
Intervention: Transoesophageal echocardiography-guided strategy with short-term anticoagulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional long-term anticoagulation
Number of subjects: 0
Study: 9017550

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day)
Number of subjects: 16000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16000
Study: 7953902

Group type: EXPERIMENTAL
Intervention: Abused and neglected individuals
Number of subjects: 699

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 699
Study: 3309752

Group type: EXPERIMENTAL
Intervention: Meclofenamate (single dose)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 18
Study: 31925771

Group type: EXPERIMENTAL
Intervention: Maternal obesity (BMI > 30 kg/m2)
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Fetal sex (male)
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Maternal BMI progression
Number of subjects: 484

Group type: COMPARATOR
Intervention: Fetal sex and maternal BMI
Number of subjects: 484
Study: 30321315

Group type: EXPERIMENTAL
Intervention: Experimental treatment
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study: 27717113

Group type: EXPERIMENTAL
Intervention: 4 months healing time before implant placement
Number of subjects: 66

Group type: COMPARATOR
Intervention: 6 months healing time before implant placement
Number of subjects: 66
Study: 25560227

Group type: EXPERIMENTAL
Intervention: 6× weekly in-center hemodialysis (frequent HD)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: 6× weekly nocturnal hemodialysis (frequent HD)
Number of subjects: 332

Group type: COMPARATOR
Intervention: 3× weekly hemodialysis (conventional HD)
Number of subjects: 332
Study: 23497486

Group type: EXPERIMENTAL
Intervention: Web-based educational intervention for GPs including an online active learning module, moderated discussion forum, targeted specialist advice, and town-based performance feedback.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (towns not receiving the intervention).
Number of subjects: 22
Study: 21706221

Group type: EXPERIMENTAL
Intervention: High dose Divalproex sodium (up to 1,500 mg/day)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Low dose Divalproex sodium (up to 250 mg/day)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 18448393

Group type: EXPERIMENTAL
Intervention: Primary prevention alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of primary and secondary prevention
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 0
Study: 16541843

Group type: EXPERIMENTAL
Intervention: Pró‐Fono Facial Exerciser
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (bruxers without device)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Experimental bruxer group (using device)
Number of subjects: 39
Study: 14550900

Group type: EXPERIMENTAL
Intervention: nalbuphine (2.5 mg) with naloxone (0.2 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: nalbuphine (2.5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: nalbuphine (5 mg) with naloxone (0.4 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: nalbuphine (2.5 mg) with naloxone (0.4 mg)
Number of subjects: 0
Study: 10227933

Group type: EXPERIMENTAL
Intervention: Total Nissen‐Rossetti fundoplication (n = 53)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Toupet partial posterior fundoplication (n = 53)
Number of subjects: 106
Study: 8693548

Group type: EXPERIMENTAL
Intervention: Oral cyclosporine microemulsion (mean dose: 5.9 mg/kg/day, range: 3.0‐11.7 mg/kg/day)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Oral cyclosporine microemulsion
Number of subjects: 22
Study: 1860215

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg, alternate-day)
Number of subjects: 22071

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22071
Study: 6401257

Group type: EXPERIMENTAL
Intervention: Elemental diet based on Vivonex HN
Number of subjects: 70

Group type: COMPARATOR
Intervention: Polymeric diet based on Clinifeed 400
Number of subjects: 70
Study: 30153814

Group type: EXPERIMENTAL
Intervention: Self-perceived ability to handle stress and depressive mood without smoking
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Smoking status in the week before baseline
Number of subjects: 612
Study: 27632442

Group type: EXPERIMENTAL
Intervention: Cathodal high-voltage monophasic pulsed current (HVMPC) applied continuously for 50 minutes once a day, 5 times a week
Number of subjects: 49

Group type: COMPARATOR
Intervention: Sham HVMPC
Number of subjects: 49
Study: 24381040

Group type: EXPERIMENTAL
Intervention: ACT-Plan
Number of subjects: 68

Group type: COMPARATOR
Intervention: Attention-control
Number of subjects: 68
Study: 23126676

Group type: EXPERIMENTAL
Intervention: Reminiscence therapy under the Watt's protocol with adaptation to Chinese Culture (six weekly sessions of 90 minutes each)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (treated as before)
Number of subjects: 60
Study: 20546160

Group type: EXPERIMENTAL
Intervention: Inhaled sevoflurane (IS)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Glucose and non-nutritive sucking (GNNS)
Number of subjects: 59
Study: 18184957

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (50 mg intravenous every 6 hours for 5 days, then tapered over 6 days)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Placebo (administered every 6 hours for 5 days, then tapered over 6 days)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 499

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 499
Study: 15897380

Group type: EXPERIMENTAL
Intervention: Antigen alone
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Antigen plus interferon alfa‐2b
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b alone
Number of subjects: 233

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Antigen
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Positive peripheral blood mononuclear cell proliferation assay result
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Older subjects (>40 years)
Number of subjects: 233
Study: 12623811

Group type: EXPERIMENTAL
Intervention: LASIK surgery for myopia correction (varied by group)
Number of subjects: 102
Study: 10208073

Group type: EXPERIMENTAL
Intervention: Clinical hypnosis
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral (CB) coping skills training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 30
Study: 8643424

Group type: EXPERIMENTAL
Intervention: sCT (Miacalcic, Sandoz, nasal spray, 2 x 100 IU/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Flavonoids (VR, Venoruton, Zyma, 2 x 0.6 + Vit. C. 0.2/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Naproxen sodium (AP, Apranax, 2 x 0.550/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: sCT and VR
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: sCT as the first active drug
Number of subjects: 30
Study: 2141691

Group type: EXPERIMENTAL
Intervention: ipratropium bromide
Number of subjects: 22

Group type: COMPARATOR
Intervention: salbutamol
Number of subjects: 22

Group type: COMPARATOR
Intervention: 0.9% NaCl
Number of subjects: 22
Study: 343181

Group type: EXPERIMENTAL
Intervention: PGE2‐analogue SHB 286 (50‐200 microgram extravular dose)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: PGE2‐analogue SHB 286 (1000‐2000 microgram intravenous infusion)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: PGE2‐analogue SHB 286
Number of subjects: 94
Study: 30414356

Group type: COMPARATOR
Intervention: Traditional 10-second signal averaged triplicates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three metrics using increasing density of automatically measured beat-to-beat (btb) intervals
Number of subjects: 0
Study: 28885566

Group type: EXPERIMENTAL
Intervention: Cinnamon supplement (3 g/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 26338213

Group type: EXPERIMENTAL
Intervention: Orthogonality metrics (OMs) derived from convex hull, information theory, fractal dimension, correlation coefficients, nearest neighbor distances and bin-density techniques
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Clark and Evans method (nearest neighbor method)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Products of OMs
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Global metric (convex hull relative area) and local metric (box-counting fractal dimension)
Number of subjects: 47
Study: 23374027

Group type: EXPERIMENTAL
Intervention: BTDS 20 μg/h (Butrans®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BTDS 5 μg/h (Butrans®)
Number of subjects: 0
Study: 21195151

Group type: EXPERIMENTAL
Intervention: GQD-RU486
Number of subjects: 90

Group type: COMPARATOR
Intervention: RU486
Number of subjects: 90

Group type: COMPARATOR
Intervention: Vacuum aspiration
Number of subjects: 90
Study: 19329221

Group type: EXPERIMENTAL
Intervention: Docetaxel 40 mg/m² days 1 and 8 plus gemcitabine 1200 mg/m² days 1 and 8 every 21 days (arm A)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Docetaxel 50 mg/m² days 1 and 15 plus gemcitabine 1600 mg/m² days 1 and 15 every 28 days (arm B)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1200 mg/m² days 1 and 8 plus cisplatin 100 mg/m² day 2 every 21 days for 3 cycles followed by docetaxel 75 mg/m² day 1 every 21 days for 3 cycles (arm C)
Number of subjects: 165
Study: 17942364

Group type: EXPERIMENTAL
Intervention: Standard care plus intervention (SC+I)
Number of subjects: 79
Study: 15114770

Group type: EXPERIMENTAL
Intervention: Patients with heart failure and arterial hypertension
Number of subjects: 192

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 192
Study: 11590384

Group type: EXPERIMENTAL
Intervention: Inhaled steroid (440 microg fluticasone propionate [FP] twice per day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10211016

Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levobupivacaine vs Bupivacaine
Number of subjects: 0
Study: 8724019

Group type: EXPERIMENTAL
Intervention: Hyperglycaemia (blood glucose approximately equal to 15 mmol/l)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Euglycaemia
Number of subjects: 10
Study: 2331068

Group type: EXPERIMENTAL
Intervention: 22-gauge spinal needle
Number of subjects: 28

Group type: COMPARATOR
Intervention: 26-gauge spinal needle
Number of subjects: 28
Study: 452945

Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pumping (IABP)
Number of subjects: 7

Group type: COMPARATOR
Intervention: No intra-aortic balloon pumping (IABP)
Number of subjects: 7
Study: 30375104

Group type: EXPERIMENTAL
Intervention: Paddles
Number of subjects: 125

Group type: COMPARATOR
Intervention: Patches
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Manual Pressure Augmentation (MPA)
Number of subjects: 125
Study: 28329359

Group type: EXPERIMENTAL
Intervention: Exercise training intervention (52-week or 26-week)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Whole-brain analyses
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Other brain regions analysis
Number of subjects: 122
Study: 25425136

Group type: EXPERIMENTAL
Intervention: Prostatic artery embolization (PAE)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 100
Study: 22520307

Group type: EXPERIMENTAL
Intervention: Torsional ultrasound (US)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Longitudinal ultrasound (US)
Number of subjects: 2
Study: 19443246

Group type: EXPERIMENTAL
Intervention: Roland disability questionnaire (RDQ) administered at T1 and T2
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Global perceived effect (GPE) scale at T2
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Baseline RDQ scores
Number of subjects: 212

Group type: COMPARATOR
Intervention: Intervention (not specified)
Number of subjects: 212
Study: 18188743

Group type: EXPERIMENTAL
Intervention: Nicotine craving, withdrawal symptoms, and smoking urges measured daily for 30 days post-quit date.
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Quit day symptom scores for women who relapsed.
Number of subjects: 137
Study: 15933856

Group type: EXPERIMENTAL
Intervention: Dynamic exercise therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Range of motion (ROM) exercise
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (same dynamic exercise protocol)
Number of subjects: 40
Study: 12790850

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Laparoscopic mesh colposuspension (LC)
Number of subjects: 121
Study: 11034583

Group type: EXPERIMENTAL
Intervention: SB-207266 (0.5, 5, and 20 mg doses)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: SB-207266 (0.05, 0.5, or 5 mg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 8543503

Group type: EXPERIMENTAL
Intervention: Meropenem (10 to 20 mg/kg every 8 h)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Cefotaxime (100 to 150 mg/kg/day), with or without amikacin or metronidazole
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Meropenem monotherapy
Number of subjects: 170

Group type: COMPARATOR
Intervention: Cefotaxime regimens
Number of subjects: 170
Study: 2116610

Group type: EXPERIMENTAL
Intervention: GnRH-a (leuprolide acetate depot 3.75 mg every 28 days)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 7030228

Group type: EXPERIMENTAL
Intervention: Regularly cycled oscillating waterbed
Number of subjects: 14

Group type: COMPARATOR
Intervention: Non-oscillating waterbed
Number of subjects: 14
Study: 30975147

Group type: EXPERIMENTAL
Intervention: Artefan®
Number of subjects: 200

Group type: COMPARATOR
Intervention: Coartem®
Number of subjects: 200